Risks of Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Receiving Warfarin and Treated With Intravenous Tissue Plasminogen Activator.

HEMORRHAGE; TISSUE plasminogen activator; WARFARIN; STROKE; AMERICAN Heart Association; INTERNATIONAL normalized ratio; COMORBIDITY; MEDICAL research

The article presents information research conducted on the risk of intracranial hemorrhage in patients suffering from acute ischemic stroke who receive warfarin and are treated with intravenous tissue plasminogen activator. The data from the American Heart Association of the U.S. determines the risk as the function of the international normalized ratio (INR) wherein if the INR is low the patients receive warfarin. Information on the patients who received warfarin was in a more comorbid condition and also had an unadjusted rate of symptomatic intracranial hemorrhage is also presented.